Validation of the inflammatory bowel disease disability index in a population-based cohort

Gut

Volumn 66, Issue 4, 2017, Pages 588-596

  Gower Rousseau, Corinne ^a,b   Sarter, Hélène ^a,b   Savoye, Guillaume ^c   Tavernier, Noémie ^a   Fumery, Mathurin ^d   Sandborn, William J ^e,j   Feagan, Brian G ^f,j   Duhamel, Alain ^g   Guillon Dellac, Nathalie ^a,b   Colombel, Jean Frédéric ^h   Peyrin Biroulet, Laurent ⁱ   Reinisch, Walter ^j   Tilg, Herbert ^j   Kamm, Michael ^j   D'Haens, Geert ^j   Louis, Edouard ^j   Van Assche, Geert ^j   Irvine, E Jan ^j   Michetti, Pierre ^j   Hibi, Toshifumi ^j   Schölmerich, Jürgen ^j   Schreiber, Stefan ^j   Munkholm, Pia ^j   Panes, Julian ^j   Alarcos, Cieza ^j   Cosnes, Jacques ^j   Lémann, Marc ^j   Lewin, Maïté ^j   Mary, Jean Yves ^j   Pariente, Benjamin ^j   Travis, Simon ^j   Chowers, Yehuda ^j   Danese, Silvio ^j   Vecchi, Maurizio ^j   Hommes, Daan W ^j   Oresland, Tom ^j   Fletcher, Joel ^j   Loftus, Edward V ^j   Sands, Bruce E ^j   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIV LILLE   (France)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j Université de Lorraine ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONSTRUCT VALIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ENVIRONMENTAL FACTOR; FEMALE; FRENCHMAN; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE DISABILITY INDEX; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; INTRARATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; PATIENT PARTICIPATION; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; ULCERATIVE COLITIS; VALIDATION STUDY; COMPLICATION; DISABILITY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; YOUNG ADULT;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 84954290045     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310151     Document Type: Article

References (36)

1. Casellas F, López-Vivancos J, Vergara M, et al. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 1999;17:208-18.
2. Peyrin-Biroulet L. What is the patient's perspective: How important are patient-reported outcomes, quality of life and disability? Dig Dis 2010;28:463-71.
3. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis 2010;16:15-22.
4. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56.
5. Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148:37-51.
6. Services DoHaH. US Food and Drug Administration (FDA). Guidance for Industry: patients-reported outcomes measures use in medical product development to support labeling claims. In: Department of Health and Human Services (US) FaDa, Center for Drug Evaluation and Research (CDER), eds. Rockville, http://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM193282.pdf
7. Thompson PW, Pegley FS. A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. Br J Rheumatol 1991;30:298-300.
8. Noseworthy JH, Vandervoort MK, Wong CJ, et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990;40:971-5.
9. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190-7.
10. Dasgupta B, Combe B, Louw I, et al. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res (Hoboken) 2014;66:1799-807.
11. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241-7.
12. Sellin J. Disability in IBD : the devil is in the details. Inflamm Bowel Dis 2010;16:23-6.
13. Leong RWL, Huang T, Ko Y, et al. Prospective validation study of the international classification of functionning disability and health score in Crohn's disease and ulcerative colitis. J Crohns Colitis 2014;8:1237-45.
14. Beaton DE, Bombardier C, Guillemin F, et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000;25:3186-91.
15. Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis 2013;45:89-94.
16. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 1994;35:1433-8.
17. Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut 2004;53:843-8.
18. Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther 2011;33:1133-42.
19. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
20. Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12:304-10.
21. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660-6.
22. Nunnally JC, Bernstein IH, Eds. Psychometric theory. 3rd ed. New York: McGraw-Hill, 1978.
23. Giraudeau B, Mary JY. Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient. Stat Med 2001;20:3205-14.
24. de Boer AG, Wijker W, Bartelsman JF, et al. Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation. Eur J Gastroenterol Hepatol 1995;7:1043-50.
25. Hawthorne G, Osborne RH, Taylor A, et al. The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. Qual Life Res 2007;16:661-73.
26. De Vet HCW, Terwee CB, Mokkikk LB, et al. Measurement in medicine: a practical guide. New York, NY: Cambridge University Press, 2011.
27. Horn JL. A rationale and test for the number of factors in factor analysis. Psychometrika 1965;30:179-85.
28. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010;63:737-45.
29. Hernaez R. Reliability and agreement studies: a guide for clinical investigators. Gut 2015;64:1018-27.
30. Kohler F, Xu J, Silva-Withmory C, et al. Feasibility of using a checklist based on the International Classification of Functioning, Disability and Health as an outcome measure in individuals following lower limb amputation. Prosthet Orthot Int 2011;35:294-301.
31. Saketkoo LA, Escorpizo R, Keen KJ, et al. EUSTAR. International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. Rheumatology (Oxford) 2012;51:2170-6.
32. Vergara M, Montserrat A, Casellas F, et al. Development and validation of the Crohn's disease perceived work disability questionnaire. Inflamm Bowel Dis 2011;17:2350-7.
33. Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:438-44.
34. Disability and Health (World Health Organization. Document A29/INFDOCI/1; 1976 [Geneva, Switzerland].
35. Camacho EM, Verstappen SM, Lunt M, et al. Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2011;63:1745-52.
36. Fernández O, Baumstarck-Barrau K, Simeoni MC, et al. MusiQoL study group. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler 2011;17:1238-49.